PSTX (Poseida Therapeutics) Selling and Marketing Expense : $0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Poseida Therapeutics's Selling and Marketing Expense for the three months ended in Sep. 2024 was $0.0 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.

Poseida Therapeutics Selling and Marketing Expense Historical Data

The historical data trend for Poseida Therapeutics's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Selling and Marketing Expense Chart

Poseida Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Selling and Marketing Expense

Get a 7-Day Free Trial

Poseida Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Selling and Marketing Expense	Get a 7-Day Free Trial															-	-	-	-	-

Poseida Therapeutics Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Poseida Therapeutics Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » Selling and Marketing Expense

Comparable Companies

Traded in Other Exchanges

2RZ:Germany

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Executives

Mark J Gergen	director, officer: President and CBO	C/O MIRATI THERAPEUTICS INC., 9393 TOWN CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning	director	614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd	director	9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado	director	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema	officer: President, Cell Therapy	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag	director, 10 percent owner, officer: Chief Executive Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls	officer: Chief Operating Officer	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner	officer: President, Gene Therapy	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear	officer: Chief Medical Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt	officer: GC & Chief Compliance Officer	C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch	director	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025